clinical trial · NCT06374485
Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
Advanced Hepatocellular CarcinomaAU409
brief summary
This study is a Phase I, dose-escalation study of AU409 in advanced hepatocellular carcinoma patients who failed standard treatment. A '3+3' dose-escalation design will be utilized to gradually increase the dose of AU409, aiming to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of multi-dose AU409 in patients with advanced HCC.
started
May 21, 2024
primary completion
Dec 28, 2025
completion
Dec 31, 2025
last updated
Aug 26, 2025
official title
A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol